
    
      After review of the interim analysis results, the independent Data Monitoring Committee (DMC)
      recommended to stop the study based on positive efficacy findings for the primary efficacy
      endpoint according to pre-specified stopping rules. Pfizer accepted the DMC recommendation
      and made the decision to stop the study on September 7, 2011.
    
  